Review Article

Targeted Optical Imaging Agents in Cancer: Focus on Clinical Applications

Figure 4

Small molecular inhibitors. Chemical structures of (a) PARP1 labeled with BODIPY (abs = 507 nm and em = 525 nm) and (b) Hsp90 inhibitor HS-196 labeled with FITC. (c) Fluorescence imaging of the oral cavity is performed with topical application of PARPi-FL followed by an acetic acid rinse to remove any unbound contrast agent. (d) Detection of OSCC in mouse tongue in orthotopic xenograft model using fluorescence stereoscope ((c) and (d) reprinted with the permission from [70]).
(a)
(b)
(c)
(d)